• 作者：Naveed Z. Janjua ; DrPH^a ; ^b ; ^{naveed.janjua@bccdc.ca" class="auth_mail" title="E-mail the corresponding author} ; Margot Kuo ; MPH^a ; Amanda Yu ; MSc^a ; Maria Alvarez ; MSc^a ; Stanley Wong ; MSc^a ; Darrel Cook ; MSc^a ; Jason Wong ; MD^a ; ^b ; Jason Grebely ; PhD^c ; Zahid A. Butt ; PhD^a ; ^b ; Hasina Samji ; PhD^a ; ^b ; Alnoor Ramji ; MD^d ; Mark Tyndall ; MD^a ; ^b ; Mel Krajden ; MD^a ; ^e
• 关键词：Cascade of care ; Hepatitis C ; Linkage with care ; Testing ; Engagement with care ; Prevalence ; Treatment
• 刊名：EBioMedicine
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：12
• 期：Complete
• 页码：189-195
• 全文大小：385 K

•

Integration of various data sources enables HCV monitoring across the care cascade to assess program effectiveness.

•

The majority of anti-HCV positive individuals were tested for RNA and genotyping.

•

Very small proportion of HCV infected individuals received treatment.

•

People with HIV coinfection and drug use despite being in liver care were less likely to receive treatment.

We have assembled data on all individuals testing for hepatitis C in British Columbia to establish a system to monitor infection and care. The majority of the individuals testing positive for anti- HCV antibodies were tested for hepatitis C RNA and subsequently genotyping, both needed for treatment. However, very small percentage received interferon-based hepatitis C treatment and it was successful in about half of them. People with HIV co-infection and drug use were more likely to receive liver care but they were less likely to receive treatment. Changes at laboratory level could overcome remaining gaps in testing while highly tolerable and effective new drugs could reduce treatment gaps.